ArriVent Historical Income Statement

AVBP Stock

29.11 0.37 1.29%

Historical analysis of ArriVent BioPharma, income statement accounts such as Selling General Administrative of 7 M, Selling And Marketing Expenses of 603.2 K or Other Operating Expenses of 44.1 M can show how well ArriVent BioPharma, Common performed in making a profits. Evaluating ArriVent BioPharma, income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ArriVent BioPharma,'s future profits or losses.

Cash Flow Balance Sheet Income Statement

ArriVent BioPharma, Net Income

(65.52 Million)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ArriVent BioPharma, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

About ArriVent Income Statement Analysis

ArriVent BioPharma, Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ArriVent BioPharma, shareholders. The income statement also shows ArriVent investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

ArriVent BioPharma, Income Statement Chart

As of 11/28/2024, Selling General Administrative is likely to drop to about 7 M. In addition to that, Other Operating Expenses is likely to drop to about 44.1 M

Selling General Administrative Selling And Marketing Expenses Other Operating Expenses Research Development

Add Fundamental

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ArriVent BioPharma,. It is also known as ArriVent BioPharma, overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from ArriVent BioPharma,'s income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ArriVent BioPharma, current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ArriVent BioPharma, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

As of 11/28/2024, Selling General Administrative is likely to drop to about 7 M. In addition to that, Other Operating Expenses is likely to drop to about 44.1 M

ArriVent BioPharma, income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Selling And Marketing Expenses	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops
Depreciation And Amortization		0.96	-0.46	0.95	-0.92	-0.85	0.95	-0.47	0.95	-0.37	0.96	-0.37	-0.96	-0.77
Selling General Administrative	0.96		-0.54	1.0	-0.96	-0.76	1.0	-0.67	1.0	-0.59	0.93	-0.59	-0.91	-0.89
Selling And Marketing Expenses	-0.46	-0.54		-0.52	0.65	0.33	-0.52	0.61	-0.52	0.56	-0.62	0.56	0.57	0.69
Other Operating Expenses	0.95	1.0	-0.52		-0.96	-0.74	1.0	-0.7	1.0	-0.62	0.91	-0.62	-0.89	-0.9
Operating Income	-0.92	-0.96	0.65	-0.96		0.82	-0.96	0.75	-0.96	0.67	-0.95	0.67	0.94	0.95
Ebit	-0.85	-0.76	0.33	-0.74	0.82		-0.73	0.34	-0.74	0.25	-0.9	0.25	0.94	0.66
Research Development	0.95	1.0	-0.52	1.0	-0.96	-0.73		-0.7	1.0	-0.63	0.9	-0.63	-0.89	-0.9
Ebitda	-0.47	-0.67	0.61	-0.7	0.75	0.34	-0.7		-0.7	0.99	-0.53	0.99	0.5	0.91
Total Operating Expenses	0.95	1.0	-0.52	1.0	-0.96	-0.74	1.0	-0.7		-0.62	0.91	-0.62	-0.89	-0.9
Income Before Tax	-0.37	-0.59	0.56	-0.62	0.67	0.25	-0.63	0.99	-0.62		-0.43	1.0	0.4	0.86
Total Other Income Expense Net	0.96	0.93	-0.62	0.91	-0.95	-0.9	0.9	-0.53	0.91	-0.43		-0.43	-1.0	-0.83
Net Income	-0.37	-0.59	0.56	-0.62	0.67	0.25	-0.63	0.99	-0.62	1.0	-0.43		0.4	0.86
Income Tax Expense	-0.96	-0.91	0.57	-0.89	0.94	0.94	-0.89	0.5	-0.89	0.4	-1.0	0.4		0.81
Net Income From Continuing Ops	-0.77	-0.89	0.69	-0.9	0.95	0.66	-0.9	0.91	-0.9	0.86	-0.83	0.86	0.81

Click cells to compare fundamentals

ArriVent BioPharma, Account Relationship Matchups

Pair Trading with ArriVent BioPharma,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will appreciate offsetting losses from the drop in the long position's value.

Moving against ArriVent Stock

0.65	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.58	FDMT	4D Molecular Therapeutics	Pair Corr
0.53	NKTX	Nkarta Inc Buyout Trend	Pair Corr
0.46	PEPG	PepGen	Pair Corr
0.44	RGNX	Regenxbio	Pair Corr

The ability to find closely correlated positions to ArriVent BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma, Common to buy it.

The correlation of ArriVent BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ArriVent BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ArriVent Stock Analysis

When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ArriVent Historical Income Statement

ArriVent BioPharma, Net Income

(65.52 Million)

About ArriVent Income Statement Analysis

ArriVent BioPharma, Income Statement Chart

Other Operating Expenses

ArriVent BioPharma, income statement Correlations

ArriVent BioPharma, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pair Trading with ArriVent BioPharma,

Moving against ArriVent Stock

Additional Tools for ArriVent Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Research Development

Income Tax Expense	- 1.0	Total Other Income Expense Net
Total Operating Expenses	- 0.96	Operating Income
Research Development	- 0.96	Operating Income
Operating Income	- 0.96	Other Operating Expenses
Operating Income	- 0.96	Selling General Administrative
Income Tax Expense	- 0.96	Depreciation And Amortization